▴ Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness.
▴ Once-daily armodafinil was effective in improving wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome (OSA) [despite treatment of the underlying condition], narcolepsy or shift work sleep disorder (SWSD) in four large (n > 195), double-blind, multinational trials of 12 weeks’ duration.
▴ Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250mg once daily in patients with OSA or narcolepsy, and with armodafinil 150mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT).
▴ Furthermore, a significantly higher proportion of armodafinil than placebo recipients achieved a response (at least a minimal improvement) on the Clinical Global Impressions of Change (CGI-C) scale at study end in these four trials (coprimary endpoint).
▴ Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Managing excessive daytime sleepiness in adults. Drug Ther Bull 2004 Jul; 42 (7): 52-6
American Academy of Sleep Medicine. International classification of sleep disorders. 2nd ed. Diagnostic and coding manual. Westchester (IL): American Academy of Sleep Medicine, 2005
Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today 2008 Jun; 44(6): 395–414
Sherman BW, Strohl KP. Management of shift work sleep disorder: Alice in Wonderland redux? J Occup Environ Med 2004 Oct; 46(10): 1010–2
Keating GM, Raffin MJ. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 2005; 19(9): 785–803
Cephalon Inc. Provigil® (modafinil tablets): US prescribing information [online]. Available from URL: http://provigil.com/media/PDFs/prescribing_info.pdf [Accessed 2009 Jun 22]
Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006 Jan; 22(1): 159–67
Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999 Mar; 39(3): 281–8
Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 Jan; 39(1): 30–40
Cephalon Inc. Nuvigil® (armodafinil tablets): US prescribing information [online]. Available from URL: http://nuvigil.com/pdf/PI.pdf [Accessed 2009 Apr 9]
Fiocchi EM, Lin YG, Aimone L, et al. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol Biochem Behav 2009 Feb 26; 92(3): S49–57
Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry 2004 Apr–Jun; 16(2): 101–9
Wisor JP, Dement WC, Aimone L, et al. R-modafinil (armodafinil) produces dose-dependent increases in wake in rat without rebound hypersomnolence [abstract no. 310.3]. 2005 Annual Meeting of the Society for Neuroscience; 2005 Nov 12–16; Washington, DC
Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009; 29(2): 87–100
Darwish M, Kriby M, Robertson Jr P, et al. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008; 47(1): 61–74
Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42(2): 123–37
US FDA. US FDA clinical review of armodafinil [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P2.pdf [Accessed 2009 Jun 24]
Roth T, Czeisler CA, Walsh JK, et al. Randomized, double-blind, placebo-controlled study of armodafinil for the treatment of excessive sleepiness associated with chronic shift work sleep disorder [abstract no. 161]. Neuropsychopharmacology 2005; 30Suppl. 1: S 140. Plus poster presented at the 44th Annual Meeting of the American College of Neuropsychopharmacology; 2005 Dec 11–15; Waikoloa (HI)
Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006 Apr; 22(4): 761–74
Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007 Mar; 101(3): 616–27
Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006 May; 28(5): 689–706
Bogan R, Hirshkowitz M, Neibler G, et al. Armodafinil improves wakefulness and memory in nCPAP compliant patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome [abstract no. 805]. Proceedings of the American Thoracic Society 2006 Apr 1; 3 (Abstr. Suppl.): 872. Plus poster presented at the International Conference of the American Thoracic Society; 2006 May 19–24; San Diego (CA)
Data on file, Cephalon Inc., 2009
Acknowledgements and Disclosures
The manuscript was reviewed by: M.D. Lemon, College of Pharmacy, South Dakota State University, Veterans Affairs Black Hills Health Care System, Fort Meade, South Dakota, USA; K.P. Strohl, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Any changes resulting from comments received were made on the basis of scientific and editorial merit.
About this article
Cite this article
Garnock-Jones, K.P., Dhillon, S. & Scott, L.J. Armodafinil. CNS Drugs 23, 793–803 (2009). https://doi.org/10.2165/11203290-000000000-00000
- Placebo Recipient
- Sleep Latency
- Final Visit